On this page

Veeva Crossix measures how biopharma media and marketing affect patient behavior and HCP prescribing. In Veeva's words, Crossix “connects advertising campaigns to clinical outcomes using health data in a privacy-safe, HIPAA-compliant way” (Veeva). If your company also sells medicines for cash through its own direct-to-patient program, ask any health-data measurement provider how those cash fills, often dispensed by partner pharmacies, appear in its data; the Veeva pages we read don't say. Curve Compliance's method looks at that channel from the partner side: each partner sends a step event such as consult, prescription or paid fill, carrying the campaign that brought the patient and no name or contact details, and the drugmaker receives aggregate results by channel, campaign and partner.

Book a call. Running a direct-to-patient program? See how partner step events become cost per paid fill by campaign against your Meta and Google Ads spend, in aggregate. Book a call with Curve.

What is Veeva Crossix?

Crossix is the marketing analytics business of Veeva Systems, which provides applications, data and consulting to the life sciences industry. Veeva announced its agreement to acquire Crossix on September 26, 2019, saying “Crossix will operate as an independent business unit under its current brand” (Veeva press release, 2019). The Crossix page lists two product families. The Crossix Measurement Suite “helps biopharma brands measure the impact of media and marketing investments on patient behavior and HCP prescribing,” and Crossix Audience Segments let healthcare marketers “reach their target audiences through advertising” (Veeva). Veeva says the Measurement Suite is available in the U.S.

The Measurement Suite has three applications. Veeva's February 2026 product sheet describes each one (Veeva product sheet, February 2026):

Crossix applicationWhat it measures, in Veeva's wordsAnnounced
Crossix Consumer Digital“biopharma direct-to-consumer digital media and brand websites”2014
Crossix HCP Digital“healthcare professional (HCP) non-personal promotion and brand websites”2017
Crossix TV“biopharma direct-to-consumer national linear TV”2019

This independent explainer describes Crossix from Veeva's public pages, read on November 20, 2026. Veeva did not write or review it; confirm details with Veeva.

What data does Crossix use?

Veeva describes a broad health and media data network, not a single data type. In its words, “The Crossix Data Platform includes Rx, clinical, claims, consumer, hospital, media data, and more, representing more than 300 million health lives” (Veeva, Crossix Data Platform). The Measurement Suite page adds that Crossix Measurement “connects longitudinal patient data on 300M+ patients and 99% of HCPs with media data from 150+ publishers and channels” (Veeva).

The Data Platform's prescription data covers “Rx (date, product, quantity, number of refills)” and “Cost (payment type, payer info)”. Other categories include clinical and EHR records, medical claims, specialty and mail order data (“Drugs distributed through specialty pharmacies”), hospital data, and media and marketing data such as TV set-top box data and digital advertising (Veeva, Crossix Data Platform).

The method, per Veeva's Consumer Digital feature brief: “By matching media exposure to actual treatment, diagnosis and clinical behavior, brands get a real-time view of campaign performance” (Veeva feature brief).

What does Crossix report for a consumer campaign?

Crossix Consumer Digital measures outbound online media, such as display, video, streaming and audio placements, along with inbound traffic to brand websites from paid and organic search and social media (Veeva, Crossix Consumer Digital). Veeva says it helps a brand “Understand if campaigns and websites are engaging the right audience and driving new patient starts,” with weekly data updates, and that “1st Party Connect enables measurement across browsers and devices, without third-party cookies.”

The feature brief lists the summary a brand team sees: “View media spend, unique reach, net new patient starts, ROI or cost per net conversion, and a campaign’s net lift” (Veeva feature brief). New patient starts matter to a direct-to-patient team too, which is why the cash-pay question below matters.

Why can claims data miss direct-to-patient cash fills?

This is a general point about insurance claims, not about any one provider. HealthVerity notes that closed claims data has been effective for analyzing initiation, adherence and persistence, “but only when prescriptions are adjudicated through insurance,” and that “When prescriptions are paid for out of pocket, they often fall outside standard pharmacy benefit workflows” (HealthVerity). In its words, “Patients who continue therapy through direct-to-consumer programs can disappear from closed payer claims data even though treatment has not stopped.” IQVIA's June 2026 obesity brief lists “Poor insight into patient access routes, including out-of-pocket purchasing, online pharmacies” among the gaps in today's data (IQVIA).

Direct-to-patient programs route those steps through partners. L.E.K. Consulting notes that “Manufacturers increasingly rely on ecosystems of specialized partners spanning telehealth, payments, pharmacy and logistics” (L.E.K.). So a cash patient's consult may happen at a telehealth partner and the fill at a partner pharmacy, outside the pharmacy benefit.

Veeva's data goes beyond claims, and its prescription fields include payment type, so the claims gap on its own doesn't tell you what Crossix can see. HealthVerity also notes that “Electronic health record (EHR) data and physician notes provide critical insight into prescribing behavior regardless of how a medication is paid for” (HealthVerity). Pin down one specific route: a cash fill, through your own program, at your partner pharmacy, credited to the campaign that started it.

What has Veeva said about direct-to-patient channels?

Veeva names the shift itself. Its September 3, 2026 blog on choosing a marketing analytics partner says: “As the pharmaceutical supply chain evolves with direct-to-patient and emerging digital channels, getting visibility into these new channels is critical.” It adds that “we continuously expand our health data network to reflect the industry’s ongoing transformation” (Veeva blog, September 3, 2026).

The same blog tells brand teams what to ask any analytics partner: “Methodology, data sources, metric definitions, statistical significance, and sample sizes make up the foundation of an advanced analytics platform,” and “brand teams should also ask these questions and look for openness and transparency from their partners” (Veeva blog, September 3, 2026).

The Veeva pages we read on November 20, 2026 don't describe how a fill paid in cash through a manufacturer's own platform, and dispensed by its partner pharmacy, is captured or credited to a campaign. That is not a finding about what Crossix covers; it is the question to put to Veeva, and to any provider, before you plan around the answer.

What should you ask a measurement provider about cash fills?

These questions apply to any provider that measures with prescription, claims or other health data, Crossix included. None of them assumes the answer.

Question to askWhy it matters for a direct-to-patient program
Does a fill paid in cash through our own direct-to-patient platform appear in your prescription data?Claims data can miss cash fills; a wider data network may or may not include your program's route.
Which pharmacies' data do you receive, and does it include the partner pharmacy that dispenses our fills?Programs rely on partner pharmacies; ask whether that pharmacy's fills reach the data.
Can results be split by payment type, cash versus insured?Veeva lists payment type among its prescription fields; ask how it shows in your reports.
If a patient moves from insurance to cash, do you count a stop, a new start or a continuing patient?HealthVerity warns: “Coverage loss can appear as treatment discontinuation.”
How do you measure an ad that sends people straight to a telehealth partner's intake, not our brand website?Veeva describes outbound online media and inbound traffic to brand websites; ask how partner-site visits are handled.
How do you define a new patient start, and how often does data refresh?Definitions decide whether two sources can be compared at all.
What are your methodology, data sources, metric definitions and sample sizes?Veeva's own blog names these as the foundation to ask about.

How do partner-reported paid fills complement health-data measurement?

Partner events measure your cash channel from the inside. In this method, each telehealth or pharmacy partner sends a stripped-down event at each step (visit, consult, prescription, paid fill) carrying the campaign that brought the patient, with no name or contact details. Matched to campaigns and Meta and Google Ads spend, they give cost per paid fill by channel, campaign and partner: a campaign's ad spend divided by the paid fills it produced over the same window.

Health-data measurement such as Crossix covers what Veeva describes: patient behavior and HCP prescribing, using data on more than 300 million patients, and channels from digital media to national linear TV (Veeva). Partner events cover the steps your own partners record. Run the two side by side, and agree which source counts which fills so none is counted twice.

Partner data has its own rules. Whether a telehealth or pharmacy partner is a HIPAA covered entity depends on how it operates; see does HIPAA apply to cash-pay telehealth companies. Agree in writing which fields each partner sends, keep reporting in aggregate, and talk to your counsel before partner data starts to flow.

How Curve Compliance helps

Curve Compliance receives outcomes from other systems through incoming webhooks and offline conversion uploads from a CRM or EHR, and credits each to the original ad click. Applied to a direct-to-patient program, a telehealth or pharmacy partner can send step events such as consult, prescription and paid fill through an incoming webhook or a file upload. In this method, each event carries the campaign that brought the patient, with no name or contact details.

Curve keeps the ad click attached when a visitor leaves your site for a booking or intake step on another system (built in for common booking tools; other systems through setup by Curve's team), and outcomes recorded days later still match. Campaign Reporting puts Meta and Google Ads spend next to the partner step events per platform and campaign, with five attribution models, so cost per paid fill by campaign sits beside the spend that produced it. The drugmaker receives aggregate results by channel, campaign and partner, including cost per paid fill.

Curve signs a BAA on every plan, holds SOC 2 Type II, and its team does the setup, typically live in about a week, case by case. See Curve for pharma and medical devices, or book a call to map your program's partner events next to the measurement you already run.

For the full setup, see direct-to-patient pharma attribution.

More on why cash-pay patients disappear from claims data.

For the full checklist, see questions to ask a direct-to-patient measurement vendor.

Sources, checked November 20, 2026: Veeva, Crossix page; Veeva, Crossix Consumer Digital page; Veeva, Crossix Data Platform page; Veeva, Crossix Consumer Digital Feature Brief; Veeva, Crossix Measurement Suite product sheet, February 2026; Veeva blog, September 3, 2026; Veeva press release, September 26, 2019; HealthVerity, January 14, 2026; IQVIA insight brief, June 2026; L.E.K. Consulting, 2026.

Frequently Asked Questions

What does Veeva Crossix measure?

Veeva Crossix measures how biopharma media and marketing affect patient behavior and HCP prescribing, by connecting advertising campaigns to clinical outcomes using health data such as prescription, clinical and claims data. Veeva sells it as the Crossix Measurement Suite (Consumer Digital, HCP Digital and TV), alongside Crossix Audience Segments for targeting.

Who owns Crossix?

Veeva Systems. Veeva announced its agreement to acquire Crossix on September 26, 2019 (Veeva press release, 2019), and today sells the Crossix Measurement Suite and Crossix Audience Segments.

Is Crossix built only on claims data?

No. Veeva says the Crossix Data Platform “includes Rx, clinical, claims, consumer, hospital, media data, and more,” and its prescription fields include payment type (Veeva, Crossix Data Platform).

Does Crossix measure direct-to-patient cash fills?

The Veeva pages we read on November 20, 2026 don't say how fills paid in cash through a manufacturer's own platform are captured, which is not a finding either way. Veeva lists payment type among its prescription fields (Veeva, Crossix Data Platform) and calls visibility into direct-to-patient channels critical (Veeva blog, September 3, 2026), so ask Veeva directly.

What is cost per paid fill?

A campaign's ad spend divided by the paid fills that campaign produced over the same window. With partner step events, it can be reported by channel, campaign and partner, against Meta and Google Ads spend.

Can partner-reported fills and health-data measurement be used together?

Yes, as two views: health-data measurement connects advertising campaigns, national TV included, to clinical outcomes; partner step events report the steps your own partners record. Agree which source counts which fills so none is counted twice.

Do partners send patient names in this method?

No. Each partner sends a stripped-down event carrying the campaign, with no name or contact details, and the drugmaker receives aggregate results by channel, campaign and partner.

Talk to Curve Compliance

Book a call. Want cost per paid fill for your direct-to-patient program next to the measurement you already run? In this method, partner step events are matched to your campaigns and reported in aggregate against your Meta and Google Ads spend. Curve signs a BAA on every plan, and its team does the setup, case by case. Book a call with Curve.